Cargando…
Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan
INTRODUCTION: Teneligliptin is a dipeptidyl peptidase 4 inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan in 2012. We performed a long-term post-marketing surveillance (RUBY) to obtain real-world evidence regarding the safety and efficacy of teneligliptin in J...
Autores principales: | Kadowaki, Takashi, Haneda, Masakazu, Ito, Hiroshi, Sasaki, Kazuyo, Matsukawa, Miyuki, Yamada, Yuka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089720/ https://www.ncbi.nlm.nih.gov/pubmed/31873865 http://dx.doi.org/10.1007/s12325-019-01189-w |
Ejemplares similares
-
Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2020) -
Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients
por: Kadowaki, Takashi, et al.
Publicado: (2018) -
Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
por: Haneda, Masakazu, et al.
Publicado: (2018) -
Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022) -
Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
por: Kadowaki, Takashi, et al.
Publicado: (2018)